Post-transplant cyclophosphamide for GVHD prophylaxis in pediatrics with chronic active Epstein-Barr virus infection after haplo-HSCT

Post-transplant cyclophosphamide for GVHD prophylaxis in pediatrics with chronic active Epstein-Barr virus infection after haplo-HSCT

Abstract Background Chronic active Epstein-Barr virus infection (CAEBV) is a rare but life-threatening progressive disease. Human leukocyte antigen (HLA)-haploidentical hematopoietic stem cell transplantation (haplo-HSCT) is the best choice as sometimes HLA-matched donor is not accessible. However,...

Full description

Bibliographic Details
Main Authors: Rongmu Luo, Xiaomei Zhang, Ya Wang, Qihang Man, Wenjing Gu, Zhengqin Tian, Jingbo Wang
Format: Article
Language:English
Published: BMC 2022-12-01
Series:Orphanet Journal of Rare Diseases
Subjects:
Chronic active Epstein-Barr virus infection
Hematopoietic stem cell transplantation
Anti-thymocyte globulin
Post-transplant cyclophosphamide
Graft-versus-host disease prophylaxis
Online Access:https://doi.org/10.1186/s13023-022-02585-2

Internet

https://doi.org/10.1186/s13023-022-02585-2

Similar Items